Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
A recent increase in the literature regarding the evidence base for clozapine has made it increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we aimed at elucidating the state-of-the-art for clozapine with regard to efficacy, effectiveness, tolerability, and management of clozapine and clozapine-related adverse events in neuropsychiatric disorders. We conducted a systematic PRISMA-conforming quantitative meta-review of available meta-analytic evidence regarding clozapine use. Primary outcome effect sizes were extracted and transformed into relative risk ratios (RR) and standardized mean differences (SMD). The methodological quality of meta-analyses was assessed using the AMSTAR-2 checklist. Of the 112 meta-analyses included in our review, 61 (54.5%) had an overall high methodological quality according to AMSTAR-2. Clozapine appears to have superior effects on positive, negative, and overall symptoms and relapse rates in schizophrenia (treatment-resistant and non-treatment-resistant subpopulations) compared to first-generation antipsychotics (FGAs) and to pooled FGAs/second-generation antipsychotics (SGAs) in treatment-resistant schizophrenia (TRS). Despite an unfavorable metabolic and hematological adverse-event profile compared to other antipsychotics, hospitalization, mortality and all-cause discontinuation (ACD) rates of clozapine surprisingly show a pattern of superiority. Our meta-review outlines the superior overall efficacy of clozapine compared to FGAs and most other SGAs in schizophrenia and suggests beneficial efficacy outcomes in bipolar disorder and Parkinson’s disease psychosis (PDP). More clinical studies and subsequent meta-analyses are needed beyond the application of clozapine in schizophrenia-spectrum disorders and future studies should be directed into multidimensional clozapine side-effect management to foster evidence and to inform future guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138 · cited 1×
“3 [21] OR and RD were transformed to RR [22] while HR and incidence rate ratio (IRR) was used as RR.”
MethodCochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636 · cited 1×
“Methodological quality assessment of included meta-analyses The Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR-2) checklist [24] was used independently by two reviewers (EW, PiyF).”
MethodThe Handbook of Research Synthesis and Meta-Analysis
(2019) · doi:10.7758/9781610448864 · Cited by 4,553
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Self-citationSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationHuhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Self-citationMeltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 1×
“Of note, meta-analytic evidence for the efficacy of clozapine in suicidal symptoms is mainly from registry data and non-randomized trials, whereas to our knowledge, only one highquality RCT [132] fosters the evidence and contributes to long-term RCT data [29].”
BackgroundVancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271
Seventy-five trials and eleven systematic reviews a day: how will we ever keep up?
Bastian, H., Glasziou, P., & Chalmers, I. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000326 · Cited by 1,188 · cited 1×
“The scientific literature regarding clozapine is vastly increasing and evidence-based psychiatry might help clinicians to judge the best evidence and decision-makers and clinicians are overstrained by the number of individual studies, reviews and meta-analyses [14].”
BackgroundPillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30416-x · Cited by 1,090
Alvares, G. A., Quintana, D. S., Hickie, I. B., & Guastella, A. J. (2016) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140217 · Cited by 503 · cited 1×
“Nevertheless, clozapine’s potential effect to cause arrhythmia [28] might be overseen, as reflected in a low amount of evidence.”
BackgroundAlmost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Autoimmune diseases, bipolar disorder, and non-affective psychosis
Eaton, W. W., Pedersen, M. G., Nielsen, P. R., & Mortensen, P. B. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00853.x · Cited by 262 · cited 1×
“patients with schizophrenia be treated with clozapine if the risk for aggressive behavior remains substantial despite other treatments [8].”
BackgroundVermeulen, J. M., van Rooijen, G., van de Kerkhof, M. P. J., Sutterland, A. L., Correll, C. U., & de Haan, L. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby052 · Cited by 246
Carbon, M., Kane, J. M., Leucht, S., & Correll, C. U. (2018) · World Psychiatry · doi:10.1002/wps.20579 · Cited by 214 · cited 4×
“2F), whereas mostly nonsignificant effects on cognition compared to FGAs and SGAs [119] were observed in RCTs and even inferior effects vs. single FGAs, e.g. sertindole [89] (see Fig.”
BackgroundInfluentialAripiprazole versus other atypical antipsychotics for schizophrenia
Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel-Kluge, C., El-Sayeh, H. G., Leucht, S., & Xia, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006569.pub5 · Cited by 151
Self-citationSiskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13522 · Cited by 144
Self-citationThe impact of clozapine on hospital use: a systematic review and meta-analysis
Land, R., Siskind, D., McArdle, P., Kisely, S., Winckel, K., & Hollingworth, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12700 · Cited by 141
Self-citationMetformin for clozapine associated obesity: a systematic review and meta-analysis
Siskind, D. J., Leung, J., Russell, A. W., Wysoczanski, D., & Kisely, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156208 · Cited by 122
Self-citationKrause, M., Huhn, M., Schneider-Thoma, J., Bighelli, I., Gutsmiedl, K., & Leucht, S. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.1105 · Cited by 86 · cited 2×
“SGAs in reducing drug abuse in schizophrenia short and medium-term [71, 118].”
BackgroundSelf-citationSalvo, F., Pariente, A., Shakir, S., Robinson, P., Arnaud, M., Thomas, S., Raschi, E., Fourrier‐Réglat, A., Moore, N., Sturkenboom, M., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.250 · Cited by 83
Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis
Chen, S.-Y., Ravindran, G., Zhang, Q., Kisely, S., & Siskind, D. (2019) · CNS Drugs · doi:10.1007/s40263-019-00612-8 · Cited by 66 · cited 1×
“Evidence is scarce for clozapine-related hypersalivation and constipation treatment [41, 49, 115] (see Fig.”
BackgroundSelf-citationClozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis
Mentzel, T. Q., van der Snoek, R., Lieverse, R., Oorschot, M., Viechtbauer, W., Bloemen, O., & van Harten, P. N. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17r11852 · Cited by 59 · cited 1×
“Of note, meta-analytic evidence suggests clozapine as favorable therapeutic antipsychotic agent for the event of TD [83].”
Background
Metadata
- Authors
- Wagner, E., Siafis, S., Fernando, P., Falkai, P., Honer, W. G., Röh, A., Siskind, D., Leucht, S., & Hasan, A.
- Venue
- Translational Psychiatry
- Published
- 2021-09-22
- Volume
- 11
- Issue
- 1
- Pages
- 487-487
- ISSN
- 2158-3188 (ISSN-L)
- OpenAlex
- W3199963285
- Cited by
- 185
- References
- 25
- FWCI
- 14.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.